1670-14-0Relevant articles and documents
Ethylene bis-imidazoles are highly potent and selective activators for isozymes VA and VII of carbonic anhydrase, with a potential nootropic effect
Draghici, Bogdan,Vullo, Daniela,Akocak, Suleyman,Walker, Ellen A.,Supuran, Claudiu T.,Ilies, Marc A.
, p. 5980 - 5983 (2014)
A series of ethylene bis-imidazoles was synthesized via a novel microwave-mediated synthesis. Biological testing on eight isozymes of carbonic anhydrase (CA) present in the human brain revealed compounds with nanomolar potency against CA VA and CA VII, also displaying excellent selectivity against other CA isozymes present in this organ. the Partner Organisations 2014.
2-methoxyphenoxy pyrimidine antitumor compound as well as preparation method and application thereof
-
Paragraph 0045; 0050-0051, (2021/05/12)
The invention belongs to the technical field of medicines, relates to a compound with anti-tumor activity and a specific chemical structure, and particularly relates to a 2-methoxyphenoxy pyrimidine compound as well as a preparation method and application thereof. The structural general formula of the 2-methoxyphenoxy pyrimidine compound is shown in the specification, wherein an R group is a hydrogen atom, or a 2-position monosubstituted fluorine atom, or 3-position and 4-position monosubstituted methyl, methoxy, fluorine atom, chlorine atom, bromine atom and iodine atom. Experimental research shows that the prepared 2-methoxyphenoxy pyrimidine compound shows a good result in an in-vitro anti-tumor activity test, has certain inhibitory activity on human malignant melanoma A375 cells, can be used for preparing anti-tumor drugs, and opens up a new way for developing new anti-tumor drugs. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.
Synthesis method of benzamidine hydrochloride
-
Paragraph 0023; 0025; 0026; 0027; 0030; 0031, (2017/12/09)
The invention discloses a synthesis method of benzamidine hydrochloride, and belongs to the field of chemical synthesis. Benzonitrile and hydroxylamine hydrochloride carry out addition reactions under the effect of an acid-binding agent and a phase transfer agent to obtain benzamidoxime; obtained benzamidoxime carries out reduction reactions at first and then is acidified to obtain a coarse product of benzamidine hydrochloride; then the coarse product is heated and dissolved in a solvent, active carbon is added into the solution to carry out color removal, then the solution is filtered, and the filtrate is dried to obtain pure benzamidine hydrochloride. The preparation method has the advantages of simpleness, green, environmental friendliness, and suitability for industrial production.
A new nonpolar N-hydroxy imidazoline lead compound with improved activity in a murine model of late-stage Trypanosoma brucei brucei infection is not cross-resistant with diamidines
Ros Martnez, Carlos H.,Miller, Florence,Ganeshamoorthy, Kayathiri,Glacial, Fabienne,Kaiser, Marcel,De Koning, Harry P.,Eze, Anthonius A.,Lagartera, Laura,Herraiz, Toms,Dardonville, Christophe
supporting information, p. 890 - 904 (2015/03/05)
Treatment of late-stage sleeping sickness requires drugs that can cross the blood-brain barrier (BBB) to reach the parasites located in the brain. We report here the synthesis and evaluation of four new N-hydroxy and 12 new N-alkoxy derivatives of bisimidazoline leads as potential agents for the treatment of late-stage sleeping sickness. These compounds, which have reduced basicity compared to the parent leads (i.e., are less ionized at physiological pH), were evaluated in vitro against Trypanosoma brucei rhodesiense and in vivo in murine models of first- and second-stage sleeping sickness. Resistance profile, physicochemical parameters, in vitro BBB permeability, and microsomal stability also were determined. The N-hydroxy imidazoline analogues were the most effective in vivo, with 4-((1-hydroxy-4,5-dihydro-1H-imidazol-2-yl)amino)-N-(4-((1-hydroxy-4,5-dihydro-1H-imidazol-2-yl)amino)phenyl)benzamide (14d) showing 100% cures in the first-stage disease, while 15d, 16d, and 17d appeared to slightly improve survival. In addition, 14d showed weak activity in the chronic model of central nervous system infection in mice. No evidence of reduction of this compound with hepatic microsomes and mitochondria was found in vitro, suggesting that N-hydroxy imidazolines are metabolically stable and have intrinsic activity against T. brucei. In contrast to its unsubstituted parent compound, the uptake of 14d in T. brucei was independent of known drug transporters (i.e., T. brucei AT1/P2 and HAPT), indicating a lower predisposition to cross-resistance with other diamidines and arsenical drugs. Hence, the N-hydroxy bisimidazolines (14d in particular) represent a new class of promising antitrypanosomal agents.